Eli Lilly and Company announced today that the European Commission has granted approval for the use of ALIMTA(R) (pemetrexed for injection) as monotherapy for maintenance treatment of patients with other than predominantly squamous cell histology in locally-advanced or metastatic non-small cell lung cancer (NSCLC), whose disease has not progressed immediately following platinum-based chemotherapy.
The details can be read here.
No comments:
Post a Comment